Patient disposition
rheumatoid
RHEUMATOID ARTHRITIS, MAY, DISEASE
Between 30 August 2018 and 28 May 2020, 91 patients were enrolled and randomised in part A of the study (TAS5315 4 mg: n=29; TAS5315 2 mg: n=29; placebo: n=33; Overall, 84 patients entered part B: 27 patients continued TAS5315 4 mg, 29 patients continued TAS5315 2 mg and 28 patients in the placebo group were randomised to TAS5315 4 mg (n=15) or 2 mg (n=13).Baseline characteristics are summarised in Demographic and baseline clinical characteristics of patients (per-protocol set)*All values are mean (±SD) and at baseline, unless otherwise stated.ACPA, anticitrullinated protein antibodies; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; hsCRP, high sensitivity C reactive protein; JSN, joint space narrowing; mTSS, modified Total Sharp Score; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; VAS, Visual Analogue Scale.